The growth-inhibitory effects of dexamethasone on renal cell carcinoma in vivo and in vitro

Cancer Investigation

Volumn 26, Issue 1, 2008, Pages 35-40

  Arai, Yasuyuki ^a   Nonomura, Norio ^a   Nakai, Yasutomo ^a   Nishimura, Kazou ^a   Oka, Daizo ^a   Shiba, Masahiro ^a   Nakayama, Masashi ^a   Takayama, Hitoshi ^a   Mizutani, Yoichi ^b   Miki, Tsuneharu ^b   Okuyama, Akihiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Dexamethasone; Glucocorticoid receptor; IL 6 (interleukin 6); NF B; Renal cell carcinoma; VEGF (vascular endothelial cell growth factor)

Indexed keywords

CYTOKINE ANTIBODY; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; PROTEIN ANTIBODY; RECEPTOR ANTIBODY; VASCULOTROPIN;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN TRANSPORT; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL PROLIFERATION; DEXAMETHASONE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; INTERLEUKIN-8; KIDNEY NEOPLASMS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NF-KAPPA B; PROTEIN TRANSPORT; RECEPTORS, GLUCOCORTICOID; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 37849033869     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701638418     Document Type: Article

References (19)

1. Motzer, R.J.; Russo, P. Systemic therapy for renal cell carcinoma. J. Urol. 2000, 163, 408-417.
2. Pizzocaro, G..; Piva, L.; Colavita, M.; Ferri, S.; Artusi, R.; Boracchi, P.; Parmian, G.; Marubini, E. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: amulticentric randomized study. J. Clin. Oncol. 2001, 19, 425-431.
3. Clark, J.I.; Atkins, M.B.; Urba, W.J.; Creech, S.; Figlin, R.A.: Dutcher, J.P.; Flaherty, L.; Sosman, J.A.; Logan, T.F.; White, R.; Weis, G.R.; Redman, B.G.; Tretter, C.P.; McDermott, D.; Smith, J.W.; Gordon, M.S.; Margolin, K.A. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J. Clin. Oncol. 2003, 21, 3133-3140.
4. Yagoda, A.; Abi-Rached, B.; Petrylak, D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin. Oncol. 1995, 22, 42-60.
5. Mizutani, Y.; Bonavida, B.; Koishihara, Y.; Akamatsu, K.; Ohsugi, Y.; Yoshida, O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res. 1995, 55, 590-596.
6. Motzer, R.J.; Michaelson, M.D.; Redman, B.G.; Hudes, G.R.; Wilding, G..; Figlin, R.A.; Ginsberg, M.S.; Kim, S.T.; Baum, C.M.; DePrimo, S.E.; Li, J.Z.; Bello, C.L.; Theuer, C.P.; George, D.J.; Rini, B.I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24, 16-24.
7. Miki, S.; Iwano, M.; Miki, Y.; Yamamoto, M.; Tang, B.; Yokokawa ,K.; Sonoda, T.; Hirano, T.; Kishimoto, T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989, 250, 607-610.
8. Blay, J.Y.; Negrier, S.; Combaret, V.; Attali, S.; Goillot, E.; Merrouche, Y.; Mercatello, A.; Ravault, A.; Tourani, J.M.; Moskovtchenko, J.F.; Phillip, T.; Favrot, M. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992, 52, 3317-3322.
9. De Bosscher, K.; Vanden, Berghe, W.; Vermeulen, L.; Plaisance, S.; Boone, E.; Haegeman, G. Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc. Natl. Sci. USA 2000, 97, 3919-3924.
10. Oya, M.; Takayanagi, A.; Horiguchi, A.; Mizuno, R.; Ohtsubo, M.; Marumo, K.; Shimizu, N.; Murai, M. Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. Carcinogenesis 2003, 24, 377-384.
11. Matsuda, M.; Osafune, M.; Nakano, E.; Kotake, T.; Sonoda, T.; Watanabe, S.; Hada, T.; Okochi, T.; Higashino, K.; Yamamura, Y.; Abe, T. Characterization of an established cell line from human renal carcinoma. Cancer Res. 1979, 39, 4694-4699.
12. Nakano, E.; Tada, Y.; Fujioka, H.; Matsuda, M.; Osafune, M.; Kotake, T.; Sato, B.; Takaha, M.; Sonoda, T. Hormone receptor in renal cell carcinoma and correlation with clinical response to endocrine therapy. J. Urol. 1984, 132, 240-245.
13. Coleman, R.E. Glucocorticoids in cancer therapy. Biotherapy 1992, 4, 37-44.
14. Nishimura, K.; Nonomura, N.; Satoh, E.; Harada, Y.; Nakayama, M.; Tokizane, T.; Fukui, T.; Ono, Y.; Inoue, H.; Shin, M.; Tsujimoto, Y.; Takayama, H.; Aozasa, K.; Okuyama, A. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J. Natl. Cancer Inst. 2001, 93, 1739-1746.
15. Nishimura, K.; Nonomura, N.; Yasunaga, Y.; Takaha, N.; Inoue, H.; Sugao, H.; Yamaguchi, S.; Ukimura, O.; Miki, T.; Okuyama, A. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 2000, 89, 2570-2576.
16. Takenawa, J.; Kaneko, Y.; Okumura, K.; Yoshida, O.; Nakayama, H.; Fujita, J. Inhibitory effect of dexamethasone and progesterone in vitro on proliferation of human renal cell carcinomas and effects on expression of interleukin-6 or interleukin-6 receptor. J. Urol. 1995, 153, 858-862.
17. Alberti, L.; Thomachot, M.C.; Bachelot, T.; Menetrier-Caux, C.; Puisieux, I.; Blay, J.Y. IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int. J. Cancer 2004, 111, 653-661.
18. Blay, J.Y.; Rossi, J.F.; Wijdenes, J.; Menetrier-Caux,C.; Schemann, S.; Negrier, S.; Philip, T.; Favrot, M. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int. J. Cancer 1997, 72, 424-430.
19. Iwai, A.; Fujii, Y.; Kawakami, S.; Takazawa, R.; Kageyama, Y.; Yoshida, M.A.; Kihara, K. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids. Mol. Cell Endocrinol. 2004, 226, 11-17.